Corporate Presentation ina jesults H1 - FY 2005 Skip IntroDisclaimer g Biocon Certain statements in this release conceming our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors nor any of their respective affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruitiong Biocon Biocon Group - Corporate Structure Pi 13% 65% | | 22% S Biocon $ 4 t 100% 51% 100% Syngene Biocon Clinigene Custom Research Biopharmaceuticals Clinical DevelopmentManagement at Biocon Vision and Execution fat g Biocon a —— jacet = a towtal eee: ea See, Meee eer an sae as = = t a ae conor Rees a aol ewer Section em Tech IT M.Se,/ PhO MIT ‘00 PhD-U.Caleuta, POF. U. Rochester a9 MBBS, MO! FRCP Landon FRCP Glasgow MBA (Bheeghom) 2000 18S: (ech) UOCT 19s (Charters Accountant ‘0Board of Directors Ensuring transparency through strong Corporate Governance & [ CHAIRMAN HORAN MAZUMDAR- SHAW Naraaing Director Bloom Grove ‘GHAIRONAN vor CouMITTEE OR. NEVILLE BAIN ‘Dredor Scotian & Newoaste Breweres Pic Recagrizd Authority in Corporate Govemance oiRECTOR ‘SURESH TALWAR Parner rawra Bayley Ce, (Soos) a DIRECTOR DR, BALA MANIAN Chatman, (Eostoundar Quantum Dot Corporation ans ‘Stiromea Corporavor, Ca¥era, USA g ‘Biocon VICE CHARMAN JOHN. ML SHAW Droeior ott. Business Dev. Biccen Group (CHAIRMAN aeuNeraTion COMMITEE PROF. CHARLES COONEY Deseo ‘Genzyme ne. & Cuno ne RECTOR PROF. RAVI MAZUNOAR Professor & Uniersiy Research Chair Dep ot Clete! & Gomauter Engineering Univers of Wateoo, Canada ALTERNATE DIRECTOR Prof Catherine Rosenberg Professor & Chaka Dep of Etec! & Computer Engneerng Univers of Wateroa, Cang ‘Biocon World-class Scientific Advisory Board CHAIRMAN PROF. CHARLES COONEY fHeae of chema & Soenemcal Engrocting NStexcones nettle o Toon DR. SAM PASTERNACK Parner Choate Hat & Stewart Patent tomaye, Boston, USA &. ‘Dr ASHOK GANGULY DBrouor ciel neuledae Pork, Mysrabad Brecor WIpRS) Sangatre le eres ‘recor st RA. Uniover ie KIRAN MAZUMDAR- SHAW Meer Goat Sen Fein oid es ‘Gharpersan, National eek Force on Be noogy Cl PROF_CHR RAO Choe Pauling Resear Prfeescr Hon: raid deteghorel No'yy Cone ror ivandes Seunie Rosca, Eagar hla DR SALA MANIAN GoFolager quanta det comoraton and Stiranas €orperaion, Calon. OR ANTHONY ALLISON Deinaulaned Scars t Surcteg Com, Forms ine Prwiiant Resear Syniee Com Inverter of Mycophenstte Not!$ Biocon Pioneering Vision 1978 1979 “1989 “1994 - India's first & No 1 Biotech company with a = 77 BIOTECHNOLOGY global Biotech ranking of 16 dee ENZYMES +. - Global leadership in specialty enzymes tf Globally unique fermentation profile - Solid State, FERMENTATION = Submerged & Mammalian Cell Culture “cuSTOM RESEARCH, ~SYNGENE: India's frst & largest Contract Research Company.Pioneering Vision $ Biocon - India’s largest and only USFDA qualified producer 1998 STATINS and exporter of Statins - CLINIGENE: India’s first CAP* accredited Clinical 2000 CLINICALRESEARCH Laboratory - First Company to post Clinical data on website - The most clinically validated r-human Insulin in India 2002 HUMAN INSULIN - Asia's largest Insulin plant in Bangalore Eee - Technology & Quality endorsement by Bristol-Myers Squibb - Co-development partnership with Nobex - India's first and largest Antibody Facility ANTIBODIES & 2003 @ANCERVACCINES > _~ Unique platform of proprietary products in as Antibodies & Cancer Vaccines * College of American PathologistsStrategic Vision - A Technology Focus $ Biocon 1. Build strong fermentation technology platforms 2. Leverage technology for product differentiation 3. Create long term value through quality & innovation 4. Chart an integrated development pathway for proprietary productsg Biocon Biocon's technology edge yy 4 \ y ‘ NE EU a eeprtaay © Mavs Recombinant Therapeutes spprecanis| Imranoe Stains © @ r-Human Insulin Enymes © © Streptokinase | GCSF sins = = Statins & Immuno- suppressants © Monadna Antdabetcs © Monecona @ Specialty food & & Industrial enzymesDelivering on a long term vision of proprietary products New drug discovery & o development ee een Resear) Generic Biopharmaceuticals eRe tee Beaune evesa eer Funding long term discovery research through a short term generic strategyGrowth Drivers $ Biocon MAbs Immuno- suppressants Research ‘Services | Statins 2004 2006 2008 2010gs Biocon: A fully integrated bio-pharma company Syngene Clinigene s Leyte a Ler) feat 1B PLAT Ce) dua eal) Re Ue) 7 (eg. Diabetes, Oncology) POE) aed (eg, Statins + Anti-diabetics) Ree iCoM ae) eed Process Regulatory Marketing pectin) ‘Scale-up. Approvals, & Sales, Biocon is positioned to become a global player within the bio-pharmaceuticals space= Financial Highlights & Analysis H1- FY 2005= $ Biocon Half Year Highlights + + t++ee t+ Sales grow by 40% to US$ 78 M Profits grow by 75% to US$ 23 M Shareholders’ funds increase to US$ 146 M All sectors (Research services, Enzymes, Statins and Biopharmaceuticals) perform strongly, Co-development partnership with Nobex to develop Oral Insulin. Phase IIB Clinical trials for h-R3 Monoclonal Antibody commenced. Launch of Biocon’s recombinant Human Insulin set for Q3. Syngene’s new research facilities completed.Revenue Break-up $ Biocon Growth 42% H1 FY 04 H1 FY 05 Custom Research MlMEnzymes Pharma Mill Other Income Ill Total Consolidated Financials as per Indian GAAPRevenue Growth gs Biocon Dynamics Contract research 6 Significant expansion of revenues from both existing & new customers. Enzymes & Speciality Enzymes continue to generate significant interest in US & Europe Biopharmaceuticals 8 Strong growth in Statins = Commencement of supply of Domestic Formulations Consolidated Financials as per Indian GAAP.$ Biocon Markets 51 (uss M) 34 27 35% 22 39% H1 FY 04 H1 FY 05 | Domestic Exports Consolidated Financials as per Indian GAAPProfit (uss m) - Improved Yields & Sales Mix - Growth in Employees & Inc in Salaries = Exchange Diff & Increase in SG&A Exps: Profit Growth - 75% ‘Consolidated Financials as per Indian GAAPThank You